<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36700810</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-8689</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Nursing</Title><ISOAbbreviation>Nursing</ISOAbbreviation></Journal><ArticleTitle>Navigating ALS: An overlooked disease.</ArticleTitle><Pagination><StartPage>24</StartPage><EndPage>30</EndPage><MedlinePgn>24-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/01.NURSE.0000905700.44849.f4</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a rare and serious disease affecting approximately 20,000 people in the US. This article details the signs, symptoms, and diagnosis of ALS and important management considerations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiper</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Valerie Kiper , Annette Gary , and Rebecca Geist are associate professors at the Texas Tech University Health Science Center (TTUHSC) School of Nursing. Kiper is also the School of Nursing's Regional Dean.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gary</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Geist</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nursing</MedlineTA><NlmUniqueID>7600137</NlmUniqueID><ISSNLinking>0360-4039</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035583" MajorTopicYN="N">Rare Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36700810</ArticleId><ArticleId IdType="doi">10.1097/01.NURSE.0000905700.44849.f4</ArticleId><ArticleId IdType="pii">00152193-202302000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The ALS Association. Understanding ALS. 2022. www.als.org/understanding-als . Accessed 2022.</Citation></Reference><Reference><Citation>Sibat HF, Valdes L. Introduction to novel aspects of motor neuron disease. In: Sibat HF, ed. Novel Aspects of Motor Neuron Disease . London, UK: IntechOpen; 2021:1&#x2013;21. doi:10.5772/intechopen.92610.</Citation></Reference><Reference><Citation>National Institute of Neurological Disorders and Stroke. www.ninds.nih.gov/ . Accessed 2022.</Citation></Reference><Reference><Citation>www.uptodate.com/contents/disease-modifying-treatment-of-amyotrophic-lateral-sclerosis?search=ALS&amp;source=search_result&amp;selectedTitle=5~150&amp;usage_type=default&amp;display_rank=5</Citation></Reference><Reference><Citation>Amyotrophic Lateral Sclerosis (ALS) Fact Sheet | National Institute of Neurological Disorders and Stroke. Ninds.nih.gov. 2022. www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet .</Citation></Reference><Reference><Citation>Martin S, Al Khleifat A, Al-Chalabi A. What causes amyotrophic lateral sclerosis. F1000Res . 2017;6:371. doi:10.12688/f1000research.10476.1.</Citation></Reference><Reference><Citation>Warner T. Motor neuron diseases. Practice Guide to Neurogenetics . 2009. www.sciencedirect.com/topics/medicine-and-dentistry/pathology-of-amyotrophic-lateral-clerosis#:~:text=Pathophysiology,thought%20to%20contain%20disarrayed%20neurofilaments .</Citation></Reference><Reference><Citation>Lockhart E. ALS: 8 ice cold facts about the fatal neurological disease. ActiveBeat. 2014. www.activebeat.com/your-health/als-8-ice-cold-facts-about-the-fatal-neurological-disease .</Citation></Reference><Reference><Citation>Paganoni S, Macklin EA, Lee A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener . 2014;15(5&#x2013;6):453&#x2013;456. doi:10.3109/21678421.2014.903974.</Citation></Reference><Reference><Citation>www.uptodate.com/contents/diagnosis-of-amyotrophic-lateral-sclerosis-and-other-forms-of-motor-neuron- disease?search=als&amp;source=search_result&amp;selectedTitle=2~150&amp;usage_type=default&amp;display_rank=2#H16</Citation></Reference><Reference><Citation>Georgetown University. The Amyotrophic Lateral Sclerosis Functional Rating Scale. www.sralab.org/sites/default/files/2017-07/PMandR_ALSRatingScale033111.pdf .</Citation></Reference><Reference><Citation>ALS Pathways. ALS information and resources. 2021. https://www.alspathways.com/als-overview/ . Accessed 2022.</Citation></Reference><Reference><Citation>Mitsubishi Tanabe Pharma America. FDA approval of RADICAVA ORS&#xae; (edaravone) for the treatment of ALS. 2022. www.prnewswire.com/ .</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration. FDA approves drug to treat ALS. 2017. www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-als .</Citation></Reference><Reference><Citation>Your ALS Guide. www.youralsguide.com/communication.html .</Citation></Reference><Reference><Citation>Galvin M, Gavin T, Mays I, Heverin M, Hardiman O. Individual quality of life in spousal ALS patient-caregiver dyads. Health Qual Life Outcomes . 2020;18(1):371. doi:10.1186/s12955-020-01551-5.</Citation></Reference><Reference><Citation>The ALS Association. Find local support for ALS. www.als.org/local-support . Accessed 2022.</Citation></Reference><Reference><Citation>ALS of Michigan. Helping people with ALS, their families, and caregivers. 2022. www.alsofmi.org/ . Accessed 2022.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Organizations that support ALS patients and caregivers. 2017. www.cdc.gov/als/OrganizationsthatSupportPALS.html . Accessed 2022.</Citation></Reference><Reference><Citation>Onesti E, Schettino I, Gori MC, et al. Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet adaptation, and Riluzole management. Front Neurol . 2017;8:94. doi:10.3389/fneur.2017.00094.</Citation></Reference><Reference><Citation>Garuti G, Rao F, Ribuffo V, Sansone VA. Sialorrhea in patients with ALS: current treatment options. Degener Neurol Neuromuscul Dis . 2019;9:19&#x2013;26. doi:10.2147/DNND.S168353.</Citation></Reference><Reference><Citation>Pan Pacific Pressure Injury Alliance. 2019 International Pressure Injury Guideline. 2019. https://pppia.org/resources/ .</Citation></Reference><Reference><Citation>Roy KM. Amotrophic lateral sclerosis and the trajectory of care. 2022. www.myamericannurse.com/als-amyotrophic-lateral-sclerosis-and-the-trajectory-of-care/ .</Citation></Reference><Reference><Citation>D'Amico E, Grosso G, Nieves JW, Zangh&#xec; A, Factor-Litvak P, Mitsumoto H. Metabolic abnormalities, dietary risk factors and nutritional management in amyotrophic lateral sclerosis. Nutrients . 2021;13(7):2273&#x2013;2293. doi:10.3390/nu13072273.</Citation></Reference><Reference><Citation>Tanenbaum B, Taft J. Maintaining good nutrition with ALS. ALS Association. www.als.org/sites/default/files/2020-04/Maintaining%20good%20nutrition%20with%20ALS.pdf .</Citation></Reference><Reference><Citation>Dorst J, Doenz J, Kandler K, et al. Fat-rich versus carbohydrate-rich nutrition in ALS: a randomised controlled study. J Neurol Neurosurg Psychiatry . 2022;93(3):298&#x2013;302. doi:10.1136/jnnp-2021-328331.</Citation></Reference><Reference><Citation>Your ALS Guide: Feeding Tubes for ALS. 2022. www.youralsguide.com/feeding-tubes.html .</Citation></Reference><Reference><Citation>Scagnelli C, Waheed W, Tandan R. Hydration in amyotrophic lateral sclerosis. In: Preedy V, Patel V, eds. Handbook of Famine, Starvation, and Nutrient Deprivation . Springer; 2019:1&#x2013;19. doi:10.1007/978-3-319-40007-5_108-1.</Citation></Reference><Reference><Citation>ALS Association. A Guide to Voice Banking Services. 2020. www.als.org/navigating-als/resources/fyi-guide-voice-banking-services .</Citation></Reference><Reference><Citation>Heidari ME, Nadali J, Parouhan A, et al. Prevalence of depression among amyotrophic lateral sclerosis (ALS) patients: a systematic review and meta-analysis. J Affect Disord . 2021;287:182&#x2013;190. doi:10.1016/j.jad.2021.03.015.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>